Lexaria Bioscience
LEXX
21 hedge funds and large institutions have $2M invested in Lexaria Bioscience in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 3 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
6.02% more ownership
Funds ownership: 7.06% → 13.08% (+6%)
5% less funds holding
Funds holding: 22 → 21 (-1)
6% less capital invested
Capital invested by funds: $2.12M → $2M (-$120K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.34M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.98K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.53K |
| 4 |
BAM
Byrne Asset Management
Kingston,
New Jersey
|
+$6.1K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$3.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
-$105K |
| 2 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$55.7K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$35.9K |
| 4 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$207 |
| 5 |
SIS
Sound Income Strategies
Ft Lauderdale,
Florida
|
-$38 |
LEXX Hedge Fund Activity: Q2 2025 in Review
21 of the 7,615 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q2 2025, worth a combined $2M — down 5.7% from $2.12M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LEXX and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 7 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.34M. The largest seller was Raymond James Financial, exiting entirely with an estimated $105K sold.
- 21 institutional investors held Lexaria Bioscience (LEXX) as of Q2 2025, down from 22 in Q1 2025.
- Funds reported $2M of Lexaria Bioscience stock for Q2 2025, down 5.7% quarter-over-quarter.
- 2 funds opened new Lexaria Bioscience positions in Q2 2025 and 3 closed out, a net change of -1 holder.
- The largest Lexaria Bioscience buyer in Q2 2025 was Sabby Management, an estimated $1.34M added.
- The largest Lexaria Bioscience seller in Q2 2025 was Raymond James Financial, an estimated $105K sold.
Based on aggregated 13F filings for Q2 2025.